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T umor tissues are comprised of tumor cells and stromal cells,  including vascular cells,  immune 
cells,  and fibroblasts [1].  Crosstalk between tumor and 
non-tumor cells creates a specialized tumor microenvi-
ronment that determines the behavior of the tumor [2].
An abundant deposition of extracellular matrix 
(ECM),  a major component of the tumor microenvi-
ronment,  is associated with cancer progression.  Since 
ECM remodeling is essential for multistep tumor 
growth,  including invasion and metastasis,  a number of 
studies have focused on matrix metalloproteinases 
(MMPs),  a family of major ECM proteases [3].  ‘A dis-
integrin-like and metalloproteinase with thrombospon-
din type 1 motif (ADAMTS)’-family proteases were 
identified as novel MMPs in a colon cancer cell line [4].  
The 19 members of the ADAMTS family play roles in 
various diseases,  including cancer [5-9].  Previous 
studies have demonstrated that,  among the ADAMTS 
family members,  ADAMTS4 and ADAMTS5 — both 
known as aggrecanases because they degrade aggrecan 
[10] — are dysregulated during cancer development 
[11 , 12].  Although ADAMTS4 and ADAMTS5 are well 
characterized as critical factors for osteoarthritis (as 
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Several research groups demonstrated that ‘a disintegrin-like and metalloproteinase with thrombospondin type 
1 motifs (ADAMTS)’-family proteases play roles in cancer progression.  However,  the origins and contributions 
of these proteases are not known.  Here,  we demonstrate an association between host-produced ADAMTS4 and 
early-stage tumor growth.  Murine Lewis lung carcinoma (LLC) tumors showed marked expressions of Adamts4 
and Adamts5.  We examined the contributions and distributions of host-derived Adamts4 and Adamts5 on tumor 
growth,  using Adamts4LacZ/LacZ and Adamts5LacZ/LacZ knockout mice.  Interestingly,  the Adamts4LacZ/LacZ mice showed 
enhanced tumor growth compared to wild-type mice at 5-,  10- and 12-days post-inoculation,  whereas the 
Adamts5LacZ/LacZ mice did not show significant differences in tumor growth.  We next examined LacZ distribution 
in LLC tumor-bearing Adamts4LacZ/LacZ mice by β-galactosidase (β-gal) staining.  We found that the β-gal-positive 
signals were strictly localized at the interior areas of the tumor at 10 days post-inoculation.  Multiple staining 
demonstrated that most of the β-gal-positive cells were localized at the tumor vasculature in Adamts4LacZ/LacZ 
mice.  Interestingly,  β-gal-positive signals were not co-localized with biglycan after 10 days post-inoculation,  
excluding the biglycan cleavage by host-derived ADAMTS4.  Taken together,  these findings illustrate that 
host-derived ADAMTS4 was expressed at the tumor vessels and was associated with early-stage tumor growth.
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aggrecanases promote the degradation of articular car-
tilage),  the origins of ADAMTS4 and ADAMTS5 and 
their contributions to tumor progression are controver-
sial [12-14].  We have sought to clarify the origins and 
contributions of host-derived ADAMTS4 and host-de-
rived ADAMTS5 in tumor progression by developing 
and characterizing Adamts4LacZ/LacZ and Adamts5LacZ/LacZ 
knockout mice.  Here,  we demonstrate that deficiency 
in host-derived ADAMTS4,  which was expressed in 
tumor vessels,  resulted in altered tumor growth.
Materials and Methods
Mouse strains and cell culture. All animal exper-
iments were approved by our institutional committee 
and adhered to the guidelines of Okayama University 
(#OKU-2017 175).  Adamts4LacZ/LacZ and Adamts5LacZ/LacZ 
mice were purchased from The Jackson Laboratory (Bar 
Harbor,  ME,  USA) and maintained in a C57BL/6 
background,  as described [15 , 16].  C57BL/6 wild-type 
mice were purchased from Charles River Japan 
(Yokohama,  Japan).  Genomic DNA was extracted from 
mouse tails,  using a DNeasy Blood & Tissue Kit 
(Qiagen,  Hilden,  Germany),  and genotyping was per-
formed using primer sets available at The Jackson 
Laboratory (Table 1).  Cells of the murine Lewis lung 
carcinoma (LLC) cell line was purchased from the 
European Collection of Authenticated Cell Cultures 
(ECACC,  Public Health England,  Salisbury,  UK).  
Cells were cultured in Dulbecco’s modified Eagle’s 
medium with 10% fetal bovine serum,  100 U/mL peni-
cillin and 100 µg/mL streptomycin in a 37°C humidi-
fied chamber (20% O2 and 5% CO2) [17].  All cells were 
maintained and used at passages 4-10.
Tumor-bearing mouse model. LLC cells 
(1.0 × 106) were inoculated in the skin of wild-type,  
Adamts4LacZ/LacZ,  and Adamts5LacZ/LacZ mice (7-12 weeks 
old).  Tumor volume was monitored every 2-3 days and 
calculated using the formula: volume = length ×  
width2 × 0.52,  as described [18-20].  Tumor tissues were 
extracted either 10 days or 14 days after inoculation.
RNA extraction and reverse transcription-poly-
merase chain reaction (RT-PCR). Total RNA was 
isolated from LLC-tumor tissues,  using TRIzol reagent 
(Thermo Fisher Scientific,  Waltham,  MA,  USA) 
[21 , 22],  and RNA concentrations were determined 
using a NanoDropTM spectrophotometer (Thermo 
Fisher Scientific).  For the detection of Adamts4 and 
Adamts5 expression,  reverse transcription-polymerase 
chain reaction (RT-PCR) was performed as described 
[23-26].  Briefly,  2 μg of RNA was reverse-transcribed 
with ReverTra Ace (Toyobo,  Osaka,  Japan),  and cDNA 
was diluted fivefold with distilled water,  as described 
[27 , 28].  The primers used for RT-PCR are shown in 
Table 2.  The reactions involved 40 cycles at 60°C for 
Adamts4 and Adamts5 and 25 cycles at 63°C for Actb.
β-galactosidase (β-gal) staining and immunohisto-
chemistry. All tissues were fixed with 4% parafor-
maldehyde for 48 h at 4°C,  incubated in 30% sucrose 
solution for 72 h at 4°C,  and cryopreserved with O.C.T.  
compound (Sakura Finetek Japan,  Tokyo,  Japan) using 
liquid nitrogen.  Tissues were sectioned to 5-10 μm by 
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Table 1　 Primers used for genotyping
Genes Primer ID Sequences
Adamts4 Sense moIMR0003 5ʼ-GGG CCA GCT CAT TCC TCC CAC TCA T-3ʼ
Adamts4 Antisense ＃1 oIMR4387 5ʼ-GCA TAC CAC TCC AAA CTT AGA GAG G-3ʼ
Adamts4 Antisense ＃2 oIMR4388 5ʼ-CGC AGC TGA CTG CTC TTG TGC TTG-3ʼ
Adamts5 Sense moIMR0012 5ʼ-GGG TGG GAT TAG ATA AAT GCC TGC TCT-3ʼ
Adamts5 Antisense ＃1 oIMR4996 5ʼ-GGA CAC GGG ATG GAC CCT CTA GAT G-3ʼ
Adamts5 Antisense ＃2 oIMR4997 5ʼ-ACA TGG AGG ACT CAG TGT GGC CCA C-3ʼ
Table 2　 Primers used for RT-PCR
Genes Sense primer Antisense primer
Adamts4 5ʼ-CATCCTACGCCGGAAGAGTC-3ʼ 5ʼ-AAGAGGCAGTGCCCATAACC-3ʼ
Adamts5 5ʼ-CCTGCCCACCCAATGGTAAA-3ʼ 5ʼ-GCAGCTGTGTAGAGTGTGGT-3ʼ
Actb 5 -TTCTACAATGAGCTGCGTGTGGC-3ʼ 5 -CTCATAGCTCTTCTCCAGGGAGGA-3ʼ
cryostat (Leica,  Wetzlar,  Germany).  For β-gal staining,  
tissues were washed with wash buffer (0.1 M phosphate 
buffer pH 7.4,  2 mM MgCl2,  0.01% Na deoxycholate,  
0.02% NP-40) and then incubated with X-gal solution 
(0.1 M phosphate buffer pH 7.4,  2 mM MgCl2,  0.01% 
sodium deoxycholate,  0.02% NP-40,  5 mM potassium 
ferrocyanide,  5 mM potassium ferricyanide,  2 mg/mL 
5-bromo-4-chloro-3-indolyl β-D-galactopyranoside) at 
37°C overnight [15].
The tissues were then washed with water three times 
for 5 min each and mounted.  Counterstaining was per-
formed with eosin.  For immunostaining using peroxi-
dase development,  endogenous peroxidase was blocked 
with 0.3% H2O2 in methanol.  Normal donkey serum 
(10%) was applied to block nonspecific binding of pro-
teins.  Tissues were incubated with primary antibody at 
4°C overnight followed by secondary antibody for 1 h at 
room temperature.
The antibodies used in this study were: rat-anti- 
CD31 antibody (1 : 200,  BD,  Biosciences,  San Jose,  CA,  
USA); rat-anti-F4/80 antibody (1 : 100,  MCA497GA,  
BioRad,  Hercules,  CA,  USA); rabbit-anti-biglycan 
LF-159 (1 : 300,  kindly provided by Drs. Larry W. 
Fisher and Marian F. Young,  U.S.  National Institutes of 
Health,  Bethesda,  MD,  USA); biotinylated rabbit 
anti-rat IgG antibody (1 : 1000,  BA-4001,  Vector,  
Burlingame,  CA,  USA),  biotinylated goat anti-rabbit 
IgG antibody (1 : 1000,  BA-1000,  Vector).
Tissues were treated with avidin-biotin complex 
(Vectastain Elite ABC kit,  PK-6100,  Vector) for 30 min.  
Immunostaining was developed using the DAB 
Substrate Kit (SK-4100,  Vector) or AEC Substrate Kit 
(SK-4200,  Vector),  and sections were mounted as 
described [29-31].  Sections were imaged using a 
microscope (model BZ-X710,  Keyence,  Osaka,  Japan) 
[32].  For multiple staining,  immunostaining was per-
formed after β-gal staining.  For biglycan staining,  tis-
sues were incubated with 0.05 U/mL chondroitinase 
ABC (Sigma Aldrich,  St. Louis,  MO,  USA; prepared 
in 0.03 M sodium acetate,  0.1 M Tris HCl,  pH 8.0) for 
1 h at 37°C.
Statistical analysis. Values are presented as the 
mean ± standard deviation (SD).  For multiple compar-
isons,  an analysis of variance (ANOVA) was per-
formed,  followed by a post-hoc analysis with the 
Bonferroni test using SigmaPlot software.  P-values 
< 0.05 were considered significant.
Results
Murine LLC expresses Adamts4 and Adamts5.
As studies have suggested that several ADAMTS prote-
ases,  including ADAMTS4 and ADAMTS5,  are dys-
regulated during cancer development,  we first exam-
ined Adamts4 and Adamts5 expression in murine LLC-
inoculated tumor tissues.  The RT-PCR results 
demonstrated marked Adamts4 and Adamts5 expression 
in LLC tumor tissues (Fig. 1).  Thus,  we used this tumor 
model to investigate the origins and contributions of 
ADAMTS in tumor progression.
Knockout of host Adamts4 but not Adamts5 signifi-
cantly enhances tumor growth. To understand the 
contributions of host ADAMTS4 and ADAMTS5,  we 
compared tumor growth in Adamts4LacZ/LacZ and 
Adamts5LacZ/LacZ mice with that in wild-type control 
mice.  The knockout of Adamts4 and Adamts5 was con-
firmed by genotyping (Fig. 2).  Interestingly,  the LLC 
tumors grown in Adamts4LacZ/LacZ mice,  which lack host- 
derived Adamts4,  had significantly increased volumes 
compared to those in the wild-type mice at 5 (p < 0.05),  
10 (p < 0.01),  and 12 (p < 0.05) days post-inoculation.  
However,  the tumor volumes did not show significant 
differences at day 14 post-inoculation (Fig. 3A , B).
These results suggest the involvement of ADAMTS4 
in early-stage tumor growth.  In contrast,  the tumors in 
the Adamts5LacZ/LacZ mice did not show significant differ-
ences in volume compared to those in the wild-type 
mice.  These results thus suggest that host ADAMTS4,  
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Fig. 1　 Adamts4 and Adamts5 mRNA expression in Lewis lung 
carcinoma (LLC) tumors.  RT-PCR of LLC-derived tumors was per-
formed with Adamts4 and Adamts5 primer sets.  A primer set for 
β-actin (Actb) was used as an internal control.  PCR products were 
electrophoresed in 2.0% agarose gels,  and the appropriately sized 
products were conﬁrmed.
but not ADAMTS5,  has an inhibitory effect on early- 
stage tumor growth.
LacZ gene expression in tumor development using 
Adamts4LacZ/LacZ and Adamts5LacZ/LacZ mice. To inves-
tigate the distribution of ADAMTS4 and ADAMTS5 in 
the tumor,  we employed LacZ reporter gene systems in 
Adamts4LacZ/LacZ and Adamts5LacZ/LacZ mice,  in which the 
Adamts4 and Adamts5 promoters regulate LacZ gene 
expression.  We performed β-gal staining to visualize 
cells expressing Adamts4 and Adamts5.  We first vali-
dated the specificity of these systems in tissues known to 
express Adamts4 and Adamts5 (the adult eye for 
Adamts4; the adult kidney for Adamts5; Fig. 4A-D).  
We then examined β-gal positivity in the tumors of 
Adamts4LacZ/LacZ and Adamts5LacZ/LacZ mice.  β-gal-positive 
signals were observed in the tumors in Adamts4LacZ/LacZ 
mice (Fig. 4E-G) at day 10 post-inoculation.  The posi-
tive signals for β-gal staining at day 10 demonstrated 
limited distribution compared to those at day 14.  That 
is,  the β-gal staining was rather clear in the interior 
region of the tumor at 10 days post-inoculation,  whereas 
the staining at day 14 was observed not only in the inte-
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Fig. 2　 Genotyping of Adamts4LacZ╱LacZ- and Adamts5LacZ╱LacZ- 
mice.  Genomic DNA was extracted from wild-type,  Adamts4LacZ╱
LacZ,  and Adamts5LacZ╱LacZ mice.  Genomic PCR was performed with 
speciﬁc primer sets for Adamts4 and Adamts5.  Ampliﬁed prod-
ucts were electrophoresed in 2.0% agarose gels,  and amplicon 
sizes were conﬁrmed.
Fig. 3　 Altered tumor growth in Adamts4-deﬁcient mice.  LLC cells 
were inoculated in the back skin of wild-type (WT),  Adamts4LacZ╱LacZ,  
and Adamts5LacZ╱LacZ mice (n＝8 for each group). A,  Tumor growth in 
each group.  ＊p＜0.05,  ＊＊p＜0.01; B,  All tumor volume data on 
days 5,  10,  and 12 are plotted and compared.  The median of the 
tumor volume is indicated.  UD: undetectable.  ＊p＜0.05,  ＊＊p＜0.01,  
N.S.,  no signiﬁcant diﬀerence.
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Fig. 4　 Histological analyses of host-derived Adamts4 and Adamt5 in the tumors.  The expressions of host-derived Adamts4 and 
Adamts5 in the LLC tumors were analyzed by a LacZ reporter analysis.  Each section was reacted with β-galactosidase (β-gal) in the 
appropriate conditions.  Tissues were counterstained with eosin; A,  β-gal activity in the eyes of Adamts4LacZ╱LacZ mice served as a positive 
control; B,  Higher magniﬁcation of the square region in (A).  Arrowheads: β-gal activity in the lens; C,  β-gal activity in the kidneys of 
Adamts5LacZ╱LacZ mice was used as a positive control; D,  Higher magniﬁcation of the square region in (C).  Arrowheads: β-gal activity in 
the glomerulus; E,  β-gal staining was performed on tumor sections from Adamts4LacZ╱LacZ mice at day 10 after inoculation; F,  Higher 
magniﬁcation of the solid square region in (E).  Arrowheads: β-gal activity; G,  Higher magniﬁcation of the dotted square region in (E).  
Note that β-gal activity was not observed in the periphery at this stage; H,  Tumor sections from Adamts4LacZ╱LacZ mice at day 14; I,  
Higher magniﬁcation of the solid square region in (H).  Arrowheads: β-gal activity; J,  Higher magniﬁcation of the dotted square region in 
(H).  Note that β-gal activity was observed in the periphery as well at a later stage (arrowheads); K,  β-gal staining was performed on 
tumor sections from Adamts5LacZ╱LacZ mice; L,  β-gal staining was performed on tumor sections from wild-type mice.
rior but also at the periphery of the tumors (Fig. 4H-J).
In contrast,  the tumors in the Adamts5LacZ/LacZ mice 
demonstrated little β-gal activity (Fig. 4K).  Tumors in 
the wild-type mice served as a negative control,  show-
ing no β-gal activity (Fig. 4L).  Therefore,  host-derived 
ADAMTS4,  but not host-derived ADAMTS5,  was 
considerably expressed in the tumor tissues and showed 
a unique distribution change in the tumor develop-
ment.
Host ADAMTS4 localization at the tumor vascular 
endothelial cells. For the clarification of the role of 
ADAMTS4,  it is important to identify which cells 
express ADAMTS4 in the tumor tissue.  We thus next 
examined the co-staining of β-gal staining with an 
endothelial cell marker (CD31) and a macrophage 
marker (F4/80) in the Adamts4LacZ/LacZ tumors.  Inter-
estingly,  most of the β-gal-positive cells were co-stained 
with CD31 in the tumors at day 10,  indicating that 
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Fig. 5　 Adamts4 was distributed in the tumor vessels.  A,  CD31 immunostaining and F4/80 immunostaining (brown) was performed after 
β-gal staining (blue) using tumor sections from Adamts4LacZ╱LacZ mice at day 10 post-inoculation.  Note that β-gal staining was observed 
mainly in the CD31-positive cells.  Arrowheads: β-gal-positive cells; B,  CD31 immunostaining was performed after β-gal staining using 
tumor sections from Adamts4LacZ╱LacZ mice at days 14.  Arrowheads: β-gal activity (blue) in endothelial cells positive for CD31 (brown).  
Scale bar＝100μm.
Adamts4 was expressed by endothelial cells on day 10 
(Fig. 5A).  In contrast,  there was no clear co-staining 
between β-gal and F4/80 in the tumors at day 10 
(Fig. 5A).  Similarly,  most of the β-gal-positive cells 
were CD31-positive in the tumors at 14 days post-inoc-
ulation (Fig. 5B).  Thus,  the majority of the Adamts4-
expressing cells were endothelial cells.
Biglycan distribution in tumor vascular endothelial 
cells. Because ADAMTS4 is a metalloproteinase,  we 
next examined its substrate,  biglycan,  in the tumor 
tissue.  Biglycan,  a small leucine-rich repeat proteogly-
can,  was reported to be expressed in tumor vessels [33].  
Biglycan and ADAMTS4 were reported to play a role in 
an in vitro angiogenesis model [34].  Here we performed 
serial section staining for β-gal staining and biglycan 
immunostaining.  In the Adamts4LacZ/LacZ tumors at day 
10,  β-gal-positive cells were concentrated at interior 
areas (Fig. 6A-C),  as also shown in Fig. 4.
Our immunostaining using an anti-biglycan anti-
body demonstrated limited biglycan distribution in the 
tumor periphery at 10 days after inoculation (Fig. 6D-F).  
In contrast,  biglycan in the tumor 14 days after inocu-
lation became more widely distributed in the tumor 
tissue (Fig. 6G , H).  We also compared the localization 
of biglycan with β-gal activity in Adamts4LacZ/LacZ tumors 
and found that biglycan and β-gal signals were differ-
ently distributed at day 10,  and biglycan co-localized 
with β-gal signals at day 14.  Taken together,  our find-
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Fig. 6　 Distribution of biglycan and Adamts4 in the tumor tissue.  A,  β-gal staining in tumor sections from Adamts4LacZ╱LacZ mice at day 
10 post-inoculation.  Interior and periphery regions of the tumor are shown; B,  Higher magniﬁcation of the solid square region in (A).  
Arrowheads: β-gal-positive cells; C,  Higher magniﬁcation of the dotted square region in (A).  Note that no β-gal activity was observed 
at day 10.  ＊The vessel cavit; D,  Immunostaining for biglycan was performed using tumor serial sections from Adamts4ˡacZ╱ˡacZ mice at day 
10 post-inoculation; E,  Higher magniﬁcation of the solid square region in (D); F,  Higher magniﬁcation of the dotted square region in (D).  
Note that biglycan was distributed in the tumor periphery at day 10.  ＊The vessel cavity; G,  Immunostaining for biglycan was performed 
after β-gal staining in tumor sections from Adamts4LacZ╱LacZ mice at day 14.  Biglycan was localized at vessel-like structures positive for β
-gal activity; H,  Higher magniﬁcation of the square region in (G).  ＊The vessel cavity.  Scale bar＝100 μm.
ings suggest that (1) tumor vessel endothelial cells (i.e.,  
the host origin) express ADAMTS4,  and (2) biglycan 
cleavage is not involved in the early stage (i.e.,  day 10) 
of tumor growth.
Discussion
Our study identified that host-derived ADAMTS4,  
not ADAMTS5,  was expressed in the tumor vessels,  
and a lack of ADAMTS4 enhanced early-stage tumor 
growth.  Although both ADAMTS4 and ADAMTS5 
have been implicated in cancer,  the details have not 
been elucidated.  Our study is the first to report that 
host-derived ADAMTS4,  but not host-derived 
ADAMTS5,  plays a role in tumor growth.
We performed β-gal staining to determine LacZ 
expression,  which replaced the Adamts4 or Adamts5 
gene in the knockout mice.  This analysis is advanta-
geous because it does not require a target molecule- 
specific antibody [15].  In addition,  this method can 
distinguish host-derived target molecules’ distribution 
from that of tumor cell-derived target molecules with 
high sensitivity and high specificity in tumor-bearing 
mouse models.  Because the tumor microenvironment 
is comprised of various cell types,  including tumor cells 
and mesenchymal cells,  it can be difficult to determine 
the localization of host-derived molecules in the tumor 
tissue.  This analysis enabled the identification of the 
precise localization of host Adamts4 and Adamts5.  LacZ 
was markedly localized to endothelial cells in the 
tumors,  indicating the distribution of host-derived 
Adamts4 in our model.  From this point of view,  this 
method is superior to immunohistochemistry.
Many studies have reported that metalloproteinases 
are produced by tumor cells and play fundamental roles 
in tumor dissemination [3].  ADAMTS4 is expressed in 
many types of cancers [35 , 36].  Rao et al.  reported that 
ADAMTS4 and its proteolytic fragments differentially 
affect tumor growth [13].  They used an ADAMTS4-
transfected tumor cell implantation model and demon-
strated that full-length ADAMTS4 promotes tumor 
growth and angiogenesis,  whereas the C-terminal 
region of ADAMTS4 inhibits tumor growth.
Fernández-Rodríguez et al.  reported that stroma- 
derived ADAMTS1 plays a role in tumor growth [37].  
There is no report demonstrating the relevance of 
host-derived ADAMTS4 and ADAMTS5; we therefore 
decided to examine the effect of host-derived 
ADAMTS4 and ADAMTS5 using Adamts4LacZ/LacZ mice 
and Adamts5LacZ/LacZ mice.  We did not elucidate the effect 
of ADAMTS4 cleavage in our system,  as we focused on 
the role of ADAMTS4 produced by host cells.
What is the role of host-derived ADAMTS4 in 
tumor growth? One possible answer is that it acts as a 
metalloprotease in the tumor vessels.  Since ADAMTS4 
is a major protease that degrades proteoglycans,  it is 
thought to contribute to the clearance and remodeling 
of proteoglycans.  Interestingly,  previous investigations 
have demonstrated that biglycan,  a chondroitin sulfate 
or dermatan sulfate proteoglycan,  is a major substrate 
of ADAMTS4 [38] and that both biglycan and 
ADAMTS4 are associated with angiogenesis.  We thus 
compared the histological distribution of biglycan by 
immunohistochemistry with that of Adamts4 by β-gal 
staining.  Interestingly,  biglycan and β-gal staining 
demonstrated different distributions at the early stage 
(day 10) of tumor growth.  This result indicated that 
biglycan is not likely to be a substrate in the tumor ves-
sels at the early stage.
Our results may indicate an unknown substrate of 
ADAMTS4 at the early stage of tumor growth,  includ-
ing ADAMTS4 cleavage itself.  On the other hand,  we 
observed considerable biglycan accumulation in tumor 
vessels at the later stage (day 14),  and these vessels were 
positive for β-gal in the Adamts4LacZ/LacZ tumors.  Inter-
estingly,  we observed that the proteoglycan versican,  
another possible substrate of ADAMTS4,  also accumu-
lates in the vasculature (Asano et al.,  data in submis-
sion).  These data may suggest a role of host-derived 
ADAMTS4 at the later stage of tumor development.
There are several ADAMTS family members that 
share high homology with ADAMTS4.  ADAMTS5 was 
reported to play a role in tumor angiogenesis by down- 
regulating VEGF expression [39].  Kumar et al.  reported 
that ADAMTS5 functions as an anti-angiogenic and 
anti-tumorigenic protein [40].  In our experimental 
model,  the tumor growth in the Adamts5LacZ/LacZ mice 
was not significantly different from that of the wild-type 
mice.  Because β-gal activity was not detected in the 
tumor tissue in the Adamts5LacZ/LacZ mice,  we think that 
the host cells were not primarily expressing ADAMTS5,  
resulting in the lack of a significant difference in the 
tumor growth.
Our findings demonstrated that the tumor growth in 
the Adamts4LacZ/LacZ mice was significantly different at 
early stages but not at the later stage.  This may suggest 
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cooperative roles for multiple ADAMTS members at 
later stages of tumor growth,  while ADAMTS4 is 
important for early-stage growth.  Detailed analyses of 
the early stages of tumor development in Adamts4LacZ/LacZ 
mice and analyses using combinational ADAMTS 
knockout mice may provide additional information 
regarding the functions of ADAMTS4 in tumor growth.
In conclusion,  our findings suggest that host- 
derived ADAMTS4,  but not ADAMTS5,  plays a role in 
early-stage tumor growth.  Our study sheds light on the 
possible roles of host cells in the tumor microenviron-
ment.  The relationship between tumor-derived and 
host-derived ADAMTS4 will be clarified in future 
research.
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